ArticleTranslational andrology and urology2025
Long-term testosterone pellet insertion in women with low libido shows no evidence of erythrocytosis and a minimal side effect profile.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Testosterone therapy for low libido in women has become increasingly prevalent in recent years. While numerous testosterone formulations exist and have been studied in women, there has been little data assessing the safety and efficacy of subcutaneous testosterone pellet use in this population. The primary objective of this study is to understand the biochemical effects and side effect profile of female patients who underwent testosterone pellet insertion in a clinical practice. Methods: A retrospective chart review of female patients who underwent testosterone pellet insertion from 2009 to 2022 was undertaken. Women taking 75 and 100 mg testosterone pellets were identified and analyzed for biochemical and clinical data. Analysis of variance was performed to determine statistical significance of laboratory values over duration of testosterone pellet insertion. Results: A total of 220 pellet insertions were performed across the two cohorts. The administration of 75 mg testosterone pellets did not result in a significant change in trough testosterone levels (P=0.51) compared to baseline throughout the treatment period, nor did it significantly affect hematocrit levels (P=0.96) or systolic blood pressure (SBP) (P=0.87). Two patients (10.5%) reported genitourinary side effects during the study period. In the cohort receiving 100 mg testosterone pellets, a significant increase in testosterone levels was observed over the study period (P=0.01), with no significant changes in hematocrit (P=0.78) or SBP (P=0.70). Two patients in this group were initiated on new antihypertensive medications during the course of treatment. No adverse effects were reported. Conclusions: Testosterone pellets of 100 mg result in a statistically significant increase in testosterone levels. Neither the 75 nor 100 mg doses led to a significant increase in erythrocytosis or SBP. Additionally, both dosages are associated with minimal side effects. These findings suggest that regulated testosterone pellet administration offers a safe biochemical profile for women with low libido.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.